/PRNewswire/ PTC Therapeutics, Inc. (NASDAQ: PTCT) today presented pooled placebo data from multiple studies in which the results confirmed the clinical.
Share this article
Share this article
SOUTH PLAINFIELD, N.J., June 9, 2021 /PRNewswire/ PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the election of Mary L. Smith to the Company s Board of Directors. Ms. Smith has previously served as the Principal Deputy Director and CEO equivalent at the Indian Health Service, a $6 billion division of the U.S. Department of Health and Human Services (HHS) and system of hospitals providing healthcare to more than two million Native Americans in the United States. Ms. Smith currently serves as Vice Chair at the VENG Group, a non-partisan government relations and public affairs firm where she consults clients on business development, strategy, healthcare and corporate governance.
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2021 Financial Results
News provided by
Share this article
Share this article
SOUTH PLAINFIELD, N.J., April 20, 2021 /PRNewswire/ PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter 2021 financial results and provide an update on the company s business and outlook on Tuesday, May 4, 2021 at 4:30 p.m. (ET) after the closing of the market.
The call can be accessed by dialing (877) 303-9216 (domestic) or (973) 935-8152 (international) five minutes prior to the start of the call and providing the passcode 4292410. A live, listen-only webcast of the conference call can be accessed on the investor relations section of the PTC website at https://ir.ptcbio.com/events-presentations. A webcast replay of the call will be available approximately two hours after completion of the call and will be archived on the company s website for 30 days
Share this article
Share this article
SOUTH PLAINFIELD, N.J., April 14, 2021 /PRNewswire/ PTC Therapeutics, Inc. (NASDAQ: PTCT) today introduced a new no-charge, patient-initiated testing program in the United States for individuals who have symptoms consistent with, or a diagnosis of, cerebral palsy (CP) with no evidence of brain injury.
CP is a group of disorders that affect a person s ability to move and maintain balance and posture. Many of the common symptoms of CP are similar to other neurotransmitter disorders, such as Aromatic L-amino Acid Decarboxylase (AADC) deficiency, resulting in potential misdiagnosis. The program, PTC Pinpoint Direct™-CP Spectrum, is an innovative, genetic testing program which includes expert genetic counseling at no charge for eligible patients.